Literature DB >> 14996727

Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment.

Christophe F Chantrain1, Hiroyuki Shimada, Sonata Jodele, Susan Groshen, Wei Ye, David R Shalinsky, Zena Werb, Lisa M Coussens, Yves A DeClerck.   

Abstract

Advanced stages of neuroblastoma show increased expression of matrix metalloproteinases MMP-2 and MMP-9, that have been implicated in many steps of tumor progression, suggesting that they play a contributory role. Using pharmacological and genetic approaches, we have examined the role of these MMPs in progression of SK-N-BE (2).10 human neuroblastoma tumors orthotopically xenotransplanted into immunodeficient mice. Mice treated with Prinomastat, a synthetic inhibitor of MMPs, showed an inhibition of tumor cell proliferation in implanted tumors and a prolonged survival (50 versus 39 days in control group, P < 0.035). Treatment with Prinomastat did not affect formation of liver metastases (P = 0.52) but inhibited intravascular colonization by the tumor cells in the lung by 73.8% (P = 0.03) and angiogenesis in both primary tumors and experimental liver metastases. The primary tumors from Prinomastat-treated mice showed a 39.3% reduction in endothelial area detected by PECAM/CD31 staining in tumor sections (P < 0.001), primarily due to the presence of smaller vessels (P = 0.004). MMP-2 is expressed by neuroblastoma tumor cells and stromal cells, whereas MMP-9 is exclusively expressed by stromal cells, particularly vascular cells. To examine the contribution of MMP-9 to tumor angiogenesis, we generated RAG1/MMP-9 double-deficient mice. We observed a significant inhibition of angiogenesis in the immunodeficient RAG1/MMP-9 double-deficient mice orthotopically implanted with tumor cells (P = 0.043) or implanted s.c. with a mixture of tumor cells and Matrigel (P < 0.001). Using an FITC-labeled lectin, we demonstrated an inhibition in the architecture of the tumor vasculature in MMP-9-deficient mice, resulting in fewer and smaller blood vessels. These changes were associated with a 48% decrease in pericytes present along microvessels. Taken together, the data demonstrate that in neuroblastoma, stromally derived MMP-9 contributes to angiogenesis by promoting blood vessel morphogenesis and pericyte recruitment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14996727     DOI: 10.1158/0008-5472.can-03-0160

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  77 in total

1.  Stromelysin-1 (MMP-3) is a target and a regulator of Wnt1-induced epithelial-mesenchymal transition (EMT).

Authors:  Laurence Blavier; Alisa Lazaryev; Xiang-He Shi; Frederick J Dorey; Gregory M Shackleford; Yves A DeClerck
Journal:  Cancer Biol Ther       Date:  2010-07-29       Impact factor: 4.742

Review 2.  Matrix metalloproteinases and the regulation of tissue remodelling.

Authors:  Andrea Page-McCaw; Andrew J Ewald; Zena Werb
Journal:  Nat Rev Mol Cell Biol       Date:  2007-03       Impact factor: 94.444

Review 3.  Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy.

Authors:  Megumi Iiizumi; Wen Liu; Sudha K Pai; Eiji Furuta; Kounosuke Watabe
Journal:  Biochim Biophys Acta       Date:  2008-07-22

4.  IL-6-mediated induction of matrix metalloproteinase-9 is modulated by JAK-dependent IL-10 expression in macrophages.

Authors:  Poonam Kothari; Roberto Pestana; Rim Mesraoua; Rim Elchaki; K M Faisal Khan; Andrew J Dannenberg; Domenick J Falcone
Journal:  J Immunol       Date:  2013-11-27       Impact factor: 5.422

Review 5.  Regulation of uterine matrix metalloproteinase-9 and the role of microRNAs.

Authors:  Warren B Nothnick
Journal:  Semin Reprod Med       Date:  2008-10-24       Impact factor: 1.303

6.  Involvement of matrix metalloproteinases on the inhibition of cells invasion and migration by emodin in human neuroblastoma SH-SY5Y cells.

Authors:  Hsu-Feng Lu; Kuang-Chi Lai; Shu-Chun Hsu; Hui-Ju Lin; Chao-Lin Kuo; Ching-Lung Liao; Jai-Sing Yang; Jing-Gung Chung
Journal:  Neurochem Res       Date:  2009-03-17       Impact factor: 3.996

Review 7.  Three-dimensional context regulation of metastasis.

Authors:  Janine T Erler; Valerie M Weaver
Journal:  Clin Exp Metastasis       Date:  2008-09-24       Impact factor: 5.150

8.  Polymorphisms in MMP9 and SIPA1 are associated with increased risk of nodal metastases in early-stage cervical cancer.

Authors:  Rebecca Brooks; Nora Kizer; Loan Nguyen; Atthapon Jaishuen; Karolyn Wanat; Elizabeth Nugent; Perry Grigsby; Jenifer E Allsworth; Janet S Rader
Journal:  Gynecol Oncol       Date:  2009-11-10       Impact factor: 5.482

9.  Neutrophil MMP-9 proenzyme, unencumbered by TIMP-1, undergoes efficient activation in vivo and catalytically induces angiogenesis via a basic fibroblast growth factor (FGF-2)/FGFR-2 pathway.

Authors:  Veronica C Ardi; Philippe E Van den Steen; Ghislain Opdenakker; Bernhard Schweighofer; Elena I Deryugina; James P Quigley
Journal:  J Biol Chem       Date:  2009-07-16       Impact factor: 5.157

10.  Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors.

Authors:  Yonatan Y Mahller; Sachin S Vaikunth; Maria C Ripberger; William H Baird; Yoshinaga Saeki; Jose A Cancelas; Timothy M Crombleholme; Timothy P Cripe
Journal:  Cancer Res       Date:  2008-02-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.